文末小调研
✩ 本文仅供医疗卫生等专业人士参考
[4m：mat-cn-2515701] 批准日期：2025 年 9 月
本编号仅作为赛诺菲对本文章所涉及的赛诺菲相关药物所属治疗领域科学和临床数据来源真实性的确认，不作为赛诺菲对本文章全部内容准确性、时效性和完整性的确认和保证；本文章仅供医疗卫生专业人士为学术交流或了解医学资讯目的使用，不构成对任何药物或治疗方案的推荐和推广。本文章所含信息不应代替医疗卫生专业人士提供的医疗建议。
内容策划：田晓宇
内容审核：张君
题图来源：企业提供
参考文献
[1] 中国医药教育协会慢性气道疾病专业委员会，中国哮喘联盟. 重度哮喘诊断与处理中国专家共识（2024）. 中华医学杂志，2024，104(20):1759-1789. doi:10.3760/cma.j.cn112137-20231117-01120
[2] 包淑钧,唐昊. 支气管哮喘气道重塑病理改变的研究进展[j]. 国际呼吸杂志,2022,42(10)：775-779.doi:10.3760/cma.j.cn131368-20210428-00336
[3] Çolak y, afzal s, marott jl, vestbo j, nordestgaard bg, lange p. type-2 inflammation and lung function decline in chronic airway disease in the general population. thorax. 2024 mar 15;79(4):349-358. doi: 10.1136/thorax-2023-220972. pmid: 38195642; pmcid: pmc10958305.
[4] hong ys, park hy, ryu s, et al. the association of blood eosinophil counts and fev1 decline: a cohort study. eur respir j. 2024;63(5):2301037. published 2024 may 30. doi:10.1183/13993003.01037-2023
[5] bacharier lb, maspero jf, katelaris ch, et al. dupilumab in children with uncontrolled moderate-to-severe asthma. n engl j med. 2021;385(24):2230-2240. doi:10.1056/nejmoa2106567
[6] bachert c, han jk, desrosiers m, et al. efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (liberty np sinus-24 and liberty np sinus-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. lancet. 2019;394(10209):1638-1650. doi:10.1016/s0140-6736(19)31881-1
[7] alberto papi, et al. early treatment response to dupilumab on airway inflammation, airway dynamics, and mucus plugging in vestige. 2024 ers poster 3933.
[8] de prado gomez l, pavord i, busse w, et al. long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma: atlas trial design. erj open res. 2023;9(2):00417-2022. published 2023 mar 6. doi:10.1183/23120541.00417-2022
